Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Stock Has Average Price Target of $18.20

Key Points

• Analysts rate Brainsway “Moderate Buy,” with five buys and two holds and an average 12-month price target of $18.20—above the stock’s $12.50 opening price.
• Brainsway exceeded quarterly expectations, reporting $0.14 EPS versus the $0.10 consensus and revenue of $17.11 million compared with estimates of $16.54 million.
• Institutional investors increased their holdings, and funds now own 30.11% of the company; Brainsway develops Deep TMS systems for treating brain disorders including depression and OCD.

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report) have been given an average rating of "Moderate Buy" by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $18.20.

Several research firms have recently weighed in on BWAY. BTIG Research reiterated a "buy" rating and set a $20.00 price objective on shares of Brainsway in a research report on Thursday, September 10th. HC Wainwright restated a "buy" rating and issued a $19.00 target price on shares of Brainsway in a report on Tuesday, September 8th. Zacks Research cut shares of Brainsway from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 11th. New Street Research reiterated a "buy" rating on shares of Brainsway in a report on Friday, July 24th. Finally, Wall Street Zen upgraded Brainsway from a "hold" rating to a "buy" rating in a report on Sunday, August 2nd.

Brainsway Price Performance

NASDAQ BWAY opened at $12.50 on Friday. The business has a fifty day moving average price of $14.44 and a two-hundred day moving average price of $14.76. Brainsway has a fifty-two week low of $7.14 and a fifty-two week high of $17.40. The stock has a market capitalization of $502.36 million, a PE ratio of 28.41 and a beta of 1.29.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The firm had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million. As a group, sell-side analysts expect that Brainsway will post 0.33 earnings per share for the current year.

Hedge Funds Weigh In On Brainsway

Institutional investors and hedge funds have recently made changes to their positions in the stock. Masters Capital Management LLC grew its stake in Brainsway by 65.0% in the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company's stock valued at $21,928,000 after acquiring an additional 650,000 shares during the period. Renaissance Technologies LLC raised its position in shares of Brainsway by 87.2% during the first quarter. Renaissance Technologies LLC now owns 518,420 shares of the company's stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Y.D. More Investments Ltd lifted its holdings in shares of Brainsway by 136.6% in the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company's stock worth $3,615,000 after purchasing an additional 157,042 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Brainsway by 262.5% in the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company's stock worth $3,009,000 after purchasing an additional 163,925 shares in the last quarter. Finally, Tidal Investments LLC grew its position in Brainsway by 492.8% in the 2nd quarter. Tidal Investments LLC now owns 89,248 shares of the company's stock valued at $1,384,000 after purchasing an additional 74,193 shares during the period. Institutional investors own 30.11% of the company's stock.

About Brainsway

BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its principal technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is designed to reach deeper and broader regions than conventional transcranial magnetic stimulation.

The company's product portfolio includes Deep TMS systems, treatment coils, and related software and accessories. Its systems are used by mental health professionals for conditions including major depressive disorder, obsessive-compulsive disorder, and smoking cessation, subject to applicable regulatory clearances and local requirements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.